Clinical Trials Browser

Phase 1/2 × Glioblastoma × contrast agent BR1 × Clear all

NCT06329570 2024-03-26

Safety and Efficacy of Bevacizumab in Combination With NaviFUS System for the Treatment of Recurrent Glioblastoma Multiforme (rGBM)

Phase 1/2 Not yet recruiting

Brain Neoplasms, Glioblastoma, Glioma, Neoplasms, Neoplasms, Nerve Tissue